|
|
|
Volumn 16, Issue 12, 2010, Pages
|
|
Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ADJUVANT CHEMOTHERAPY;
ADULT;
ARTICLE;
BREAST TUMOR;
COMPARATIVE STUDY;
COST BENEFIT ANALYSIS;
DECISION SUPPORT SYSTEM;
DISEASE COURSE;
DNA MICROARRAY;
ECONOMICS;
FEMALE;
GENE EXPRESSION PROFILING;
HUMAN;
MIDDLE AGED;
MORTALITY;
PROBABILITY;
PROGNOSIS;
QUALITY OF LIFE;
REGISTER;
RISK ASSESSMENT;
RISK REDUCTION;
SURVIVAL;
UNITED STATES;
ADULT;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
COST-BENEFIT ANALYSIS;
DECISION SUPPORT TECHNIQUES;
DISEASE PROGRESSION;
FEMALE;
GENE EXPRESSION PROFILING;
HUMANS;
MARKOV CHAINS;
MIDDLE AGED;
OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;
PROGNOSIS;
QUALITY OF LIFE;
REGISTRIES;
RISK ASSESSMENT;
RISK REDUCTION BEHAVIOR;
SURVIVAL ANALYSIS;
UNITED STATES;
YOUNG ADULT;
|
|
EID: 79957823551
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (41)
|
|
References (0)
|
